Amneal Pharmaceuticals, Inc.
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
AMRX$21.38+0.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Cash Flows
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities: | ||
| Net income | $78,000 | $24,618 |
| Adjustments to reconcile net income to net cash (used in) provided by operating activities: | ||
| Depreciation and amortization | 43,191 | 60,159 |
| Unrealized foreign currency loss (gain) | 8,215 | (3,596) |
| Amortization of debt issuance costs and discount | 3,890 | 6,811 |
| Reclassification of cash flow hedge | 2,878 | (6,444) |
| Loss on refinancing | 3,510 | — |
| Stock-based compensation | 8,816 | 7,258 |
| Inventory provision | 13,353 | 23,669 |
| Other operating charges and credits, net | 1,486 | 1,313 |
| Changes in assets and liabilities: | ||
| Trade accounts receivable, net | 44,013 | 21,148 |
| Inventories | (54,959) | (13,263) |
| Prepaid expenses, other current assets and other assets | (13,400) | (513) |
| Related party receivables | (56) | (2) |
| Accounts payable, accrued expenses and other liabilities | (124,578) | (112,626) |
| Related party payables | (41,102) | (1,124) |
| Net cash (used in) provided by operating activities | (26,743) | 7,408 |
| Cash flows from investing activities: | ||
| Purchases of property, plant and equipment | (8,175) | (13,162) |
| Acquisition of intangible assets | (7,850) | (4,200) |
| Deposits for future acquisition of property, plant and equipment | (5,685) | (960) |
| Proceeds from sale of property, plant and equipment | — | 524 |
| Net cash used in investing activities | (21,710) | (17,798) |
| Cash flows from financing activities: | ||
| Payments of principal on debt, revolving credit facilities, financing leases and other | (140,842) | (235,528) |
| Proceeds from issuance of debt | 134,673 | — |
| Payments of deferred financing and refinancing costs | (1,982) | — |
| Borrowings on revolving credit facilities | — | 218,000 |
| Proceeds from exercise of stock options | 38 | 69 |
| Employee payroll tax withholding on restricted stock unit vesting | (44,305) | (21,639) |
| Tax and other distributions to non-controlling interests | (7,147) | (68) |
| Proceeds from alliance party | 510 | — |
| Net cash used in financing activities | (59,055) | (39,166) |
| Effect of foreign exchange rate on cash | (1,023) | (470) |
| Net decrease in cash, cash equivalents, and restricted cash | (108,531) | (50,026) |
| Cash, cash equivalents, and restricted cash - beginning of period | 312,939 | 118,420 |
| Cash, cash equivalents, and restricted cash - end of period | $204,408 | $68,394 |
| Cash and cash equivalents - end of period | $197,656 | $59,187 |
| Restricted cash - end of period | 4,174 | 6,583 |
| Long-term restricted cash included in other assets - end of period | 2,578 | 2,624 |
| Cash, cash equivalents, and restricted cash - end of period | $204,408 | $68,394 |
Consolidated Statements of Cash Flows (continued)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for interest | $56,450 | $56,323 |
| Cash received (paid), net for income taxes | $2,453 | $(3,613) |
| Supplemental disclosure of non-cash investing and financing activity: | ||
| Tax distributions to non-controlling interests | $— | $4,806 |
| Acquisition of product rights and licenses | $1,350 | $1,700 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.